{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:28:26Z","timestamp":1793633306341,"version":"4.5.1"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.thromres.2026.109622","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:11:28Z","timestamp":1771258288000},"page":"109622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["aPLs seroconversion in antiphospholipid syndrome: from definition to clinical relevance"],"prefix":"10.1016","volume":"259","author":[{"given":"Angela","family":"Di Giorgio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Carnuccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Nesci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Santoliquido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2026.109622_bb0005","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/bmj.287.6399.1088","article-title":"Thrombosis, abortion, cerebral disease, and the lupus anticoagulant","volume":"287","author":"Hughes","year":"1983","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2026.109622_bb0010","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.thromres.2026.109622_bb0015","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/art.40901","article-title":"The epidemiology of antiphospholipid syndrome: a population-based study","volume":"71","author":"Duarte-Garc\u00eda","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.thromres.2026.109622_bb0020","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/rheumatology\/key082","article-title":"The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients","volume":"57","author":"Rodr\u00edguez-Pint\u00f3 I","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.thromres.2026.109622_bb0025","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1177\/0961203320950461","article-title":"16th International Congress on Antiphospholipid Antibodies Task Force report on antiphospholipid syndrome treatment trends","volume":"29","author":"Cohen","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.thromres.2026.109622_bb0030","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2026.109622_bb0035","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/03009742.2022.2082114","article-title":"Patients with laboratory criteria of anti-phospholipid syndrome and \u2018non-criteria\u2019 manifestations: a multicenter cohort","volume":"52","author":"Pires Da Rosa","year":"2023","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.thromres.2026.109622_bb0040","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-022-02726-9","article-title":"Non-criteria manifestations in primary antiphospholipid syndrome: a French multicenter retrospective cohort study","volume":"24","author":"Gu\u00e9don","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.thromres.2026.109622_bb0045","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.16308","article-title":"Addendum to British Society for Haematology guidelines on investigation and management of antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47\u201358): use of direct-acting oral anticoagulants","volume":"189","author":"Arachchillage","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2026.109622_bb0050","doi-asserted-by":"crossref","first-page":"e938","DOI":"10.1016\/S2352-3026(24)00281-3","article-title":"Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants","volume":"11","author":"Ageno","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.thromres.2026.109622_bb0055","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jtha.2024.09.029","article-title":"Thrombotic complications in pregnancy: a case-based review of the evidence","volume":"23","author":"Merz","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109622_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2023.02.005","article-title":"Recurrent thrombotic events after disappearance of antiphospholipid autoantibodies: a long-term longitudinal study in patients with antiphospholipid syndrome","volume":"224","author":"Ballul","year":"2023","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2026.109622_bb0065","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1157\/13115821","article-title":"Retirada de la anticoagulaci\u00f3n en el s\u00edndrome antifosfol\u00edpido primario cuando se negativizan los anticuerpos anticardiolipina","volume":"208","author":"Criado-Garc\u00eda","year":"2008","journal-title":"Rev. Clin. Esp."},{"key":"10.1016\/j.thromres.2026.109622_bb0070","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12026-013-8407-x","article-title":"Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative","volume":"56","author":"Coloma Baz\u00e1n","year":"2013","journal-title":"Immunol. Res."},{"key":"10.1016\/j.thromres.2026.109622_bb0075","doi-asserted-by":"crossref","first-page":"SI96","DOI":"10.1093\/rheumatology\/kead538","article-title":"Anticoagulant and non-anticoagulant therapy in thrombotic antiphospholipid syndrome: old drugs and new treatment targets","volume":"63","author":"Ruiz-Irastorza","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.thromres.2026.109622_bb0080","article-title":"The additional use of hydroxychloroquine can improve the live birth rate in pregnant women with persistent positive antiphospholipid antibodies: a systematic review and meta-analysis","volume":"0","author":"Tian","year":"2021","journal-title":"J. Gynecol. Obstet. Hum. Reprod."},{"key":"10.1016\/j.thromres.2026.109622_bb0085","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.semarthrit.2016.02.002","article-title":"Rituximab usage in systemic lupus erythematosus-associated antiphospholipid syndrome: a single-center experience","volume":"46","author":"Wang","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.thromres.2026.109622_bb0090","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/annrheumdis-2019-216367","article-title":"Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus","volume":"79","author":"Chatzidionysiou","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.thromres.2026.109622_bb0095","article-title":"Sirolimus monotherapy for thrombocytopenia in primary antiphospholipid syndrome: a pilot study from a tertiary referral center","volume":"13","author":"Xie","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.thromres.2026.109622_bb0100","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109622_bb0105","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/jth.13976","article-title":"Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH","volume":"16","author":"Devreese","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109622_bb0110","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.autrev.2017.02.004","article-title":"Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: thrombosis recurrence","volume":"16","author":"Medina","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.thromres.2026.109622_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102798","article-title":"B cells in primary antiphospholipid syndrome: review and remaining challenges","volume":"20","author":"Dieudonn\u00e9","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.thromres.2026.109622_bb0120","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000693","article-title":"Increased B-cell activating factor (BAFF)\/B-lymphocyte stimulator (BLyS) in primary antiphospholipid syndrome is associated with higher adjusted global antiphospholipid syndrome scores","volume":"4","author":"Van Den Hoogen","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.thromres.2026.109622_bb0125","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1097\/CM9.0000000000000948","article-title":"Change of serum B-cell activating factor level in patients with positive antiphospholipid antibodies and previous adverse pregnancy outcomes and its significance","volume":"133","author":"Li","year":"2020","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.thromres.2026.109622_bb0130","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/art.23764","article-title":"Prevention of murine antiphospholipid syndrome by BAFF blockade","volume":"58","author":"Kahn","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.thromres.2026.109622_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100610","article-title":"The role of beta-2-glycoprotein I in health and disease associating structure with function: more than just APS","volume":"39","author":"McDonnell","year":"2020","journal-title":"Blood Rev."},{"key":"10.1016\/j.thromres.2026.109622_bb0140","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.atherosclerosissup.2017.05.039","article-title":"Serum of patients with antiphospholipid syndrome induces adhesion molecules in endothelial cells","volume":"30","author":"Engel","year":"2017","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/j.thromres.2026.109622_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/cells11081288","article-title":"Anti-\u03b22-GPI antibodies induce endothelial cell expression of tissue factor by LRP6 signal transduction pathway involving lipid rafts","volume":"11","author":"Riitano","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.thromres.2026.109622_bb0150","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s11926-013-0324-4","article-title":"Inhibition of nitric oxide and antiphospholipid antibody-mediated thrombosis","volume":"15","author":"Mineo","year":"2013","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.thromres.2026.109622_bb0155","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2026.109622_bb0160","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0961203319897958","article-title":"New insights into antiphospholipid-related endothelial dysfunction by assessment of vascular glycocalyx layer: results from a preliminary cross-sectional study","volume":"29","author":"Miranda","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.thromres.2026.109622_bb0165","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.molimm.2012.08.012","article-title":"Anti-\u03b22GPI\/\u03b22GPI induced TF and TNF-\u03b1 expression in monocytes involving both TLR4\/MyD88 and TLR4\/TRIF signaling pathways","volume":"53","author":"Xie","year":"2013","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.thromres.2026.109622_bb0170","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1111\/jth.13865","article-title":"Antiphospholipid antibody-induced cellular responses depend on epitope specificity: implications for treatment of antiphospholipid syndrome","volume":"15","author":"M\u00fcller-Calleja","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109622_bb0175","doi-asserted-by":"crossref","DOI":"10.1172\/JCI200318817","article-title":"Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome","volume":"112","author":"Girardi","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.thromres.2026.109622_bb0180","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1126\/science.1092385","article-title":"Neutrophil extracellular traps kill bacteria","volume":"303","author":"Brinkmann","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.thromres.2026.109622_bb0185","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.jtha.2023.05.024","article-title":"Anti\u2013\u03b22-glycoprotein I and anti-phosphatidylserine\/prothrombin antibodies interfere with cleavage of factor V(a) by activated protein C","volume":"21","author":"Noordermeer","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109622_bb0190","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.thromres.2022.08.004","article-title":"Antiphospholipid syndrome: reversal of antiphosphatidylserine\/prothrombin-induced activated protein C resistance","volume":"218","author":"Pontara","year":"2022","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2026.109622_bb0195","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/jth.15241","article-title":"Anti-\u03b22-glycoprotein I and anti-prothrombin antibodies cause lupus anticoagulant through different mechanisms of action","volume":"19","author":"Noordermeer","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109622_bb0200","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1055\/s-0041-1725098","article-title":"Impaired fibrinolysis in the antiphospholipid syndrome","volume":"47","author":"Antovic","year":"2021","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2026.109622_bb0205","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1177\/0961203313490241","article-title":"Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of \u03b22-glycoprotein I","volume":"22","author":"Wahezi","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.thromres.2026.109622_bb0210","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3389\/fimmu.2019.00449","article-title":"Complement in the pathophysiology of the antiphospholipid syndrome","volume":"10","author":"Chaturvedi","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.thromres.2026.109622_bb0215","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.placenta.2023.04.001","article-title":"Low complement levels are related to poor obstetric outcomes in women with obstetric antiphospholipid syndrome. The EUROAPS registry study group","volume":"136","author":"Esteve-Valverde","year":"2023","journal-title":"Placenta"},{"key":"10.1016\/j.thromres.2026.109622_bb0220","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS","volume":"135","author":"Chaturvedi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2026.109622_bb0225","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.3389\/fimmu.2019.01609","article-title":"Environmental triggers of autoreactive responses: induction of antiphospholipid antibody formation","volume":"10","author":"Martirosyan","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.thromres.2026.109622_bb0230","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/clinids\/24.2.197","article-title":"Antiphospholipid syndrome associated with cytomegalovirus infection: case report and review","volume":"24","author":"Labarca","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.thromres.2026.109622_bb0235","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/21505594.2017.1385691","article-title":"Antigenicity analysis of human parvovirus B19-VP1u protein in the induction of anti-phospholipid syndrome","volume":"9","author":"Lin","year":"2018","journal-title":"Virulence"},{"key":"10.1016\/j.thromres.2026.109622_bb0240","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/antib5030018","article-title":"Antiphospholipid antibodies: from general concepts to its relation with malignancies","volume":"5","author":"G\u00f3mez-Puerta","year":"2016","journal-title":"Antibodies"},{"key":"10.1016\/j.thromres.2026.109622_bb0245","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/ar4549","article-title":"Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers","volume":"16","author":"Meroni","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.thromres.2026.109622_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2018.06.010","article-title":"Subclinical atherosclerosis in asymptomatic carriers of persistent antiphospholipid antibodies positivity: a cross-sectional study","volume":"274","author":"Di Minno","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.thromres.2026.109622_bb0255","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.thromres.2026.109622_bb0260","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3899\/jrheum.161364","article-title":"Longterm outcome of patients with primary antiphospholipid syndrome: a retrospective multicenter study","volume":"44","author":"Taraborelli","year":"2017","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.thromres.2026.109622_bb0265","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1177\/0961203317699285","article-title":"Cessation of oral anticoagulants in antiphospholipid syndrome","volume":"26","author":"Comarmond","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.thromres.2026.109622_bb0270","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0961203317721751","article-title":"Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study","volume":"27","author":"Yelnik","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.thromres.2026.109622_bb0275","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1055\/s-0039-1696687","article-title":"Prevalence of antiphospholipid antibodies negativisation in patients with antiphospholipid syndrome: a long-term follow-up multicentre study","volume":"119","author":"Radin","year":"2019","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109622_bb0280","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/rheumatology\/keaa463","article-title":"Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion","volume":"60","author":"Zen","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.thromres.2026.109622_bb0285","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood-2008-03-144204","article-title":"Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers","volume":"112","author":"Rand","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2026.109622_bb0290","doi-asserted-by":"crossref","first-page":"766","DOI":"10.6061\/clinics\/2013(06)07","article-title":"Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients","volume":"68","author":"Silva","year":"2013","journal-title":"Clinics"},{"key":"10.1016\/j.thromres.2026.109622_bb0295","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0049-3848(94)90270-4","article-title":"On the inhibitory effect of chloroquine on blood platelet aggregation","volume":"74","author":"Jancinov\u00e1","year":"1994","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2026.109622_bb0300","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/jth.12363","article-title":"Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients","volume":"11","author":"Schmidt-Tanguy","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109622_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212614","article-title":"Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: role of reduced inflammation and endothelial dysfunction","volume":"14","author":"Miranda","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2026.109622_bb0310","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/annrheumdis-2016-210012","article-title":"Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase","volume":"76","author":"M\u00fcller-Calleja","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.thromres.2026.109622_bb0315","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/rheumatology\/kex378","article-title":"The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies","volume":"57","author":"Schreiber","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.thromres.2026.109622_bb0320","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1080\/14767058.2021.1908992","article-title":"Hydroxychloroquine in obstetric antiphospholipid syndrome: rationale and results of an observational study of refractory cases","volume":"35","author":"Khizroeva","year":"2022","journal-title":"J. Matern. Fetal Neonatal Med."},{"issue":"1","key":"10.1016\/j.thromres.2026.109622_bb0325","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12026-016-8812-z","article-title":"Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome","volume":"65","author":"Nuri","year":"2017","journal-title":"Immunol. Res."},{"key":"10.1016\/j.thromres.2026.109622_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102491","article-title":"The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: a pilot open label randomized prospective study","volume":"19","author":"Kravvariti","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.thromres.2026.109622_bb0335","series-title":"Seventh International Congress on SLE and Related Conditions Abstract book. M17A","article-title":"Use of hydroxychloroquine in antiphospholipid antibody syndrome at three academic rheumatology units over two years: improvement in antibody titer and symptom management [abstract]","author":"McCarty","year":"2004"},{"issue":"1","key":"10.1016\/j.thromres.2026.109622_bb0340","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11926-010-0141-y","article-title":"Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients","volume":"13","author":"Petri","year":"2011","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.thromres.2026.109622_bb0345","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3899\/jrheum.120157","article-title":"Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and\/or lupus anticoagulant in systemic lupus erythematosus","volume":"40","author":"Broder","year":"2013","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.thromres.2026.109622_bb0350","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.autrev.2015.04.010","article-title":"Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment?","volume":"14","author":"De Carolis","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.thromres.2026.109622_bb0355","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1136\/ard.2004.031856","article-title":"Real world experience with antiphospholipid antibody tests: how stable are results over time?","volume":"64","author":"Erkan","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.thromres.2026.109622_bb0360","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/art.24232","article-title":"Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies","volume":"61","author":"Tektonidou","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.thromres.2026.109622_bb0365","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.18419","article-title":"Use of intravenous immunoglobulin in antiphospholipid antibody positive patients with high risk of miscarriage: a systematic review and meta-analysis","volume":"12","author":"Yuan","year":"2024","journal-title":"PeerJ"},{"key":"10.1016\/j.thromres.2026.109622_bb0370","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/0961203317724219","article-title":"APS ACTION. Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease","volume":"27","author":"Erkan","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.thromres.2026.109622_bb0375","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.autrev.2018.05.012","article-title":"HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome","volume":"17","author":"Belizna","year":"2018","journal-title":"Autoimmun. Rev."},{"issue":"7\u20138","key":"10.1016\/j.thromres.2026.109622_bb0380","first-page":"598","article-title":"\u00c9valuation du b\u00e9n\u00e9fice de l\u2019utilisation d\u2019hydroxychloroquine pour l\u2019obtention d\u2019une grossesse \u00e0 terme non compliqu\u00e9e en cas de syndrome des antiphospholipides primaire: \u00e9tude de phase II multicentrique randomis\u00e9e en double insu versus placebo, HYDROSAPL","volume":"46","author":"Mekinian","year":"2018","journal-title":"Gynecol. Obstetr. Fertil. Senol."},{"issue":"6","key":"10.1016\/j.thromres.2026.109622_bb0385","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1055\/s-0037-1603359","volume":"43","author":"Schreiber","year":"2017","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2026.109622_bb0390","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.thromres.2026.109622_bb0395","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1093\/rheumatology\/keac551","article-title":"British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids","volume":"62","author":"Russell","year":"2023","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.thromres.2026.109622_bb0400","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/BOR.0000000000000500","article-title":"Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update","volume":"30","author":"Abdulaziz","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.thromres.2026.109622_bb0405","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900.012k14_3900_3908","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis","volume":"95","author":"Golay","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2026.109622_bb0410","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3899\/jrheum.100729","article-title":"Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab","volume":"38","author":"Iwata","year":"2011","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.thromres.2026.109622_bb0415","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02836","article-title":"\u03b22-Glycoprotein I-reactive T cells in autoimmune disease","volume":"9","author":"Rauch","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.thromres.2026.109622_bb0420","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2007.079418","article-title":"B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response","volume":"67","author":"Cambridge","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.thromres.2026.109622_bb0425","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2026.109622_bb0430","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/0961203311400115","article-title":"Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome","volume":"20","author":"Sciascia","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.thromres.2026.109622_bb0435","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/0961203307085251","article-title":"Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature","volume":"17","author":"Erre","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.thromres.2026.109622_bb0440","first-page":"355","article-title":"Rituximab treatment for resistant antiphospholipid syndrome","volume":"33","author":"Rubenstein","year":"2006","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.thromres.2026.109622_bb0445","article-title":"Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome","volume":"89","author":"Erdozain","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2026.109622_bb0450","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.971366","article-title":"Low dose versus standard dose rituximab for the treatment of antiphospholipid syndrome: a pilot study from a tertiary medical center","volume":"13","author":"Gan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.thromres.2026.109622_bb0455","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/ard.2007.078402","article-title":"B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres","volume":"67","author":"Ioannou","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.thromres.2026.109622_bb0460","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.semarthrit.2016.08.002","article-title":"Repeated low-dose courses of rituximab in SLE-associated antiphospholipid syndrome: data from a tertiary dedicated centre","volume":"46","author":"Emmi","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.thromres.2026.109622_bb0465","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1177\/0961203311422713","article-title":"Rituximab induces resolution of recurrent diffuse alveolar hemorrhage in a patient with primary antiphospholipid antibody syndrome","volume":"21","author":"Scheiman Elazary","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.thromres.2026.109622_bb0470","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/jth.14427","article-title":"Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation","volume":"17","author":"Hisada","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109622_bb0475","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.thromres.2026.109622_bb0480","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.thromres.2026.109622_bb0485","article-title":"A rare case of refractory catastrophic antiphospholipid syndrome successfully treated with Rituximab and plasma exchange","volume":"13","author":"Bangolo","year":"2023","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"key":"10.1016\/j.thromres.2026.109622_bb0490","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12882-018-0928-z","article-title":"The complex treatment including rituximab in the Management of Catastrophic Antiphospholid Syndrome with renal involvement","volume":"19","author":"Rymarz","year":"2018","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.thromres.2026.109622_bb0495","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jbspin.2011.07.001","article-title":"Antiphospholipid syndrome development after rituximab treatment","volume":"79","author":"Faillace","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.thromres.2026.109622_bb0500","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/1759720X14554793","article-title":"Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome","volume":"7","author":"Rodr\u00edguez-Pint\u00f3","year":"2015","journal-title":"Ther. Adv. Musculoskelet."},{"key":"10.1016\/j.thromres.2026.109622_bb0505","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/24725625.2019.1648633","article-title":"A case of successful pregnancy following multidrug treatment including rituximab and intravenous immunoglobulin for primary antiphospholipid antibody syndrome refractory to conventional treatment","volume":"4","author":"Nagata","year":"2020","journal-title":"Mod. Rheumatol. Case Rep."},{"issue":"9","key":"10.1016\/j.thromres.2026.109622_bb0510","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-021-01037-3","article-title":"Long-term safety of rituximab (risks of viral and opportunistic infections)","volume":"23","author":"Varley","year":"2021","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.thromres.2026.109622_bb0515","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/art.23764","article-title":"Prevention of murine antiphospholipid syndrome by BAFF blockade","volume":"58","author":"Kahn","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.thromres.2026.109622_bb0520","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.autrev.2018.11.002","article-title":"Belimumab reduces antiphospholipid antibodies in SLE patients independently of hydroxychloroquine treatment","volume":"18","author":"Emmi","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.thromres.2026.109622_bb0525","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1136\/annrheumdis-2018-213496","article-title":"Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab","volume":"77","author":"Sciascia","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.thromres.2026.109622_bb0530","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/0961203316682102","article-title":"Belimumab in primary antiphospholipid syndrome","volume":"26","author":"Yazici","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.thromres.2026.109622_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102594","article-title":"Belimumab reduces antiphospholipid antibodies in primary triple-positive antiphospholipid syndrome","volume":"19","author":"Klemm","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.thromres.2026.109622_bb0540","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.semarthrit.2021.06.005","article-title":"Pregnancy outcomes in patients treated with belimumab: report from real-world experience","volume":"51","author":"Kao","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.thromres.2026.109622_bb0545","article-title":"Belimumab therapy for refractory immune thrombocytopenia in systemic lupus erythematosus patients with anti-phospholipid antibodies","volume":"1","author":"Dong","year":"2023","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.thromres.2026.109622_bb0550","first-page":"18","article-title":"High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets","author":"Ruffatti","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.thromres.2026.109622_bb0555","article-title":"36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature","volume":"2014","author":"Strakhan","year":"2014","journal-title":"Case Rep. Hematol."},{"key":"10.1016\/j.thromres.2026.109622_bb0560","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.2020007499","article-title":"Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab","volume":"136","author":"Yelnik","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2026.109622_bb0565","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17783","article-title":"Early use of eculizumab for catastrophic antiphospholipid syndrome","volume":"196","author":"Faguer","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.thromres.2026.109622_bb0570","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10238-019-00565-8","article-title":"Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature","volume":"19","author":"Tinti","year":"2019","journal-title":"Clin. Exp. Med."},{"issue":"6","key":"10.1016\/j.thromres.2026.109622_bb0575","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/0961203320917460","article-title":"Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature","volume":"29","author":"Skoczynska","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.thromres.2026.109622_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): descriptive analysis from the \u201cCAPS Registry.\u201d","volume":"21","author":"L\u00f3pez-Benjume","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.thromres.2026.109622_bb0585","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1182\/bloodadvances.2021005657","article-title":"Eculizumab for refractory thrombosis in antiphospholipid syndrome","volume":"6","author":"Hussain","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2026.109622_bb0590","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/ajt.12319","article-title":"Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes","volume":"13","author":"Canaud","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.thromres.2026.109622_bb0595","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006338","article-title":"Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: a case report","volume":"96","author":"Gustavsen","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.thromres.2026.109622_bb0600","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012584","article-title":"Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome: a case report","volume":"97","author":"Rovere-Querini","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.thromres.2026.109622_bb0605","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.thromres.2026.109622_bb0610","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1161\/01.CIR.99.16.2164","article-title":"Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle","volume":"99","author":"Gallo","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2026.109622_bb0615","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa067193","article-title":"Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents","volume":"356","author":"Stone","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2026.109622_bb0620","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/RHU.0000000000000409","article-title":"Stents coated with mammalian target of rapamycin inhibitors (mTOR) appear to be the best choice in patients with antiphospholipid syndrome and myocardial infarction","volume":"22","author":"Mora-Ram\u00edrez","year":"2016","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.thromres.2026.109622_bb0625","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/j.ajkd.2019.08.032","article-title":"mTORC pathway activation and effect of sirolimus on native kidney antiphospholipid syndrome nephropathy: a case report","volume":"76","author":"Dufour","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.thromres.2026.109622_bb0630","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/art.39791","article-title":"Mitochondrial dysfunction in the liver and antiphospholipid antibody production precede disease onset and respond to rapamycin in lupus-prone mice","volume":"68","author":"Oaks","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.thromres.2026.109622_bb0635","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/03009742.2019.1574022","article-title":"Successful use of sirolimus in a patient with cardiac microangiopathy in primary antiphospholipid syndrome","volume":"48","author":"Sartorelli","year":"2019","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.thromres.2026.109622_bb0640","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1055\/s-0039-1685453","article-title":"Platelet activation by antiphospholipid antibodies depends on epitope specificity and is prevented by mTOR inhibitors","volume":"119","author":"Hollerbach","year":"2019","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109622_bb0645","first-page":"1","article-title":"Corticosteroids, plasmapheresis, argatroban, rituximab, and sirolimus provided clinical benefit for catastrophic antiphospholipid syndrome in a patient with a history of heparin-induced thrombocytopenia","volume":"2023","author":"Hasan","year":"2023","journal-title":"Case Rep. Rheumatol."},{"key":"10.1016\/j.thromres.2026.109622_bb0650","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3899\/jrheum.220049","article-title":"Mammalian target of rapamycin pathway assessment in antiphospholipid antibody\u2013positive patients with livedo","volume":"49","author":"Sevim","year":"2022","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.thromres.2026.109622_bb0655","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1365-2141.2008.07074.x","article-title":"The VWF\/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction","volume":"141","author":"Austin","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.thromres.2026.109622_bb0660","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/0961203312446386","article-title":"Vitamin D and antiphospholipid syndrome","volume":"21","author":"Andreoli","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.thromres.2026.109622_bb0665","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/humrep\/det424","article-title":"Vitamin D deficiency may be a risk factor for recurrent pregnancy losses by increasing cellular immunity and autoimmunity","volume":"29","author":"Ota","year":"2014","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.thromres.2026.109622_bb0670","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.semarthrit.2017.10.007","article-title":"Vitamin D and antiphospholipid syndrome: a retrospective cohort study and meta- analysis","volume":"47","author":"Riancho-Zarrabeitia","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.thromres.2026.109622_bb0675","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jbspin.2010.02.043","article-title":"High frequency of vitamin D insufficiency in primary antiphospholid syndrome","volume":"77","author":"Klack","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.thromres.2026.109622_bb0680","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/ard.2010.134817","article-title":"Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression","volume":"70","author":"Agmon-Levin","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.thromres.2026.109622_bb0685","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1096\/fj.15-272872","article-title":"Vitamin D modulates tissue factor and protease-activated receptor 2 expression in vascular smooth muscle cells","volume":"30","author":"Martinez-Moreno","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.thromres.2026.109622_bb0690","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049318","article-title":"1,25-Dihydroxyvitamin D3 promotes a sustained LPS-induced NF-\u03baB-dependent expression of CD55 in human monocytic THP-1 cells","volume":"7","author":"Izban","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2026.109622_bb0695","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/0961203317716787","article-title":"Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies","volume":"27","author":"Watanabe","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.thromres.2026.109622_bb0700","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1002\/art.11449","article-title":"Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model","volume":"48","author":"Ferrara","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.thromres.2026.109622_bb0705","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1093\/rheumatology\/keab410","article-title":"Effect of statins on the prevention of recurrent thrombosis in thrombotic antiphospholipid syndrome","volume":"61","author":"Kwon","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.thromres.2026.109622_bb0710","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/humrep\/des288","article-title":"Pravastatin does not prevent antiphospholipid antibody-mediated changes in human first trimester trophoblast function","volume":"27","author":"Odiari","year":"2012","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.thromres.2026.109622_bb0715","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.1080\/14767058.2021.1940940","article-title":"Pravastatin is useful for prevention of recurrent severe placenta-mediated complications \u2013 a pilot study","volume":"35","author":"Kupferminc","year":"2022","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"10.1016\/j.thromres.2026.109622_bb0720","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1177\/0961203318772015","article-title":"Simvastatin reduces antiphospholipid antibodies formation in patients with systemic lupus erythematosus: a preliminary study","volume":"27","author":"Kotyla","year":"2018","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.thromres.2026.109622_bb0725","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1385\/CRIAI:29:3:229","article-title":"Intravenous immunoglobulin therapy in antiphospholipid syndrome","volume":"29","author":"Konova","year":"2005","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.thromres.2026.109622_bb0730","article-title":"Intrinsic pathway activation in patients with antiphospholipid syndrome and healthy controls","volume":"31","author":"van Mourik","year":"2025","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109622_bb0735","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS","volume":"23","author":"Chaturvedi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2026.109622_bb0740","article-title":"B-cell maturation antigen (BCMA) as a biomarker and potential treatment target in systemic lupus erythematosus","volume":"9","author":"Martin","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.thromres.2026.109622_bb0745","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.bbrc.2020.02.084","article-title":"Rapalink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy both in vivo and vitro","volume":"30","author":"Mu","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.thromres.2026.109622_bb0750","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.jtha.2025.03.029","article-title":"Lupus anticoagulant and antiprothrombin antibodies: embracing the future","volume":"23","author":"Pengo","year":"2025","journal-title":"J. Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826000411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826000411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T14:48:27Z","timestamp":1793630907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384826000411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":150,"alternative-id":["S0049384826000411"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109622","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"aPLs seroconversion in antiphospholipid syndrome: from definition to clinical relevance","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109622","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109622"}}